Editorial Board About Us

Hormonal therapy

All articles from this key word are listed below.

Volume 3, Supplement 2 Supplement

Therapeutic Strategies for Localized Prostate Cancer

John Lynch Joel Kaufman Andrew B Joel Joseph Batuello Daniel P Petrylak Leonard G Gomella E David Crawford

Prostate cancer Erectile dysfunction Hormonal therapy Prostatectomy, radical

Volume 5, Supplement 3 Supplement

Neoadjuvant Therapy for Prostate Cancer: An Oncologist's Perspective

Elizabeth C Kent Maha HA Hussain

Prostate cancer Chemotherapy Radical prostatectomy Radiotherapy Hormonal therapy Neoadjuvant therapy

Volume 7, Supplement 5 Review Articles

Adverse Events Associated With Hormonal Therapy for Prostate Cancer

Ravi J Kumar Al Barqawi E David Crawford

Prostate cancer Prevention Hormonal therapy Adverse effects

Volume 7, Supplement 5 Review Articles

Addressing the Needs of the High-Risk Prostate Cancer Patient

Leonard G Gomella

Hormonal therapy Radiation therapy Prostate cancer, high risk

Volume 8, Supplement 2 Review Articles

Hormonal Therapy for Prostate Cancer

16th International Prostate Cancer Update

Michael K Brawer

Updates on hormonal therapy in the treatment of prostate cancer are presented. The most common therapy is to reduce testosterone to castrate levels. A dosage of 1 mg diethylstilbestrol daily prolonged survival in patients with advanced prostate cancer. The leuteinizing hormone–releasing hormone agonists have essentially replaced surgical orchiectomy in the vast majority of clinical settings; however, a major problem with the leuteinizing hormone– releasing hormone agonists has been the surge and flare of testosterone levels. If hormonal therapy is initiated early, the risk of major complications is significantly decreased. Combined androgen blockade is better than monotherapy, although there is only a small clinical benefit. When androgen deprivation is used for a short time and the normal androgen milieu is re-established, the side effects and toxicity of androgen deprivation are decreased. The major complications of androgen deprivation include hot flushes, reduction of bone mineral density, osteoporosis, and anemia. Intermittent androgen blockade might have the same benefits of total androgen suppression with fewer side effects, increased duration of androgen dependence, and less cost. The 10 steps to take when advising patients about initiation of androgen deprivation therapy are reviewed. [Rev Urol. 2006;8(suppl 2):S35-S47]

Prostate cancer Hormonal therapy Androgen ablation Diethylstilbestrol

Volume 9, Number 2 Review Articles

The Impact of Definitions of Failure on the Interpretation of Biochemical Recurrence Following Treatment of Clinically Localized Prostate Cancer

Diagnostic Update

Matthew E Nielsen Alan W Partin

Widespread early detection with prostate-specific antigen (PSA) has radically transformed the clinical management of prostate cancer. PSA has become valuable in the monitoring and risk stratification of recurrent disease following local therapy. In many ways, biochemical recurrence–free survival, or PSA outcome, has become a surrogate measure of treatment efficacy following primary local therapy. Given the inherent differences in PSA kinetics following these treatment approaches, the definition of biochemical success or failure is not uniform among therapies. An appreciation of the inherent strengths, limitations, and biases of the standard definitions of failure can provide a more meaningful context within which to interpret the reported outcomes of different treatment modalities. [Rev Urol. 2007;9(2):57-62]

Prostate-specific antigen Radiotherapy Hormonal therapy Prostate cancer recurrence Biochemical failure Brachytherapy

Volume 11, Number 2 Meeting Reviews

Best of the 2009 AUA Annual Meeting

Highlights From the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL

Naoki Yoshimura F Pouliot B Shuch Arie S Belldegrun Michael K Brawer Claus G Roehrborn J Curtis Nickel Stacy Loeb Michael B Chancellor Alan W Partin Ellen Shapiro Dean G Assimos

Prostate cancer screening Obesity Benign prostatic hyperplasia Lower urinary tract symptoms Vesicoureteral reflux Nephrolithiasis Stress urinary incontinence Inflammation Silodosin Hormonal therapy Tumor markers TMPRSS2ERG 4-Kallikrein panel Botulinum toxin type A Male voiding dysfunction Benign prostatic specific antigen Roux-en-Y gastric bypass surgery Genitourinary pain index UPOINT clinical phenotype system Nephron-sparing surgery Watchful waiting Laparoscopy for adrenal cortical carcinoma Partial adrenalectomy Urethral trauma Pediatric urethral stricture Enteric urologic surgery

Volume 12, Number 1 Review Articles

Intermittent Androgen Deprivation Therapy: Redefining the Standard of Care?

Management Update

Neal D Shore E David Crawford

As a clinical strategy, intermittent androgen deprivation therapy (IADT) has the potential to minimize adverse events associated with continuous androgen deprivation therapy while providing comparable efficacy for patients with advanced prostate cancer. Because most studies supporting IADT to date have been somewhat small and underpowered, additional large, randomized, controlled trials are needed before this strategy becomes the standard of care.However, the potential advantages of IADT, which include improved quality of life, the theoretical possibility of delaying hormone resistance, and possible reduction in expenses to the patient and health care payers, suggest it is a strategy worth further exploration.[Rev Urol. 2010;12(1):1-11 doi: 10.3909/riu0490]

Prostate cancer Androgen deprivation therapy Prostate-specific antigen Testosterone Hormonal therapy